Faculty

Institution

Unit

Venue

Lydia Usha

Rush University

Affiliations

Division Of Hematology/Oncology/Cell Therapy

Rush University

NoneLydia Usha is currently serving as a Division Of Hematology/Oncology/Cell Therapy faculty at Rush University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Lydia Usha

Rush University

You can click a keyword to filter the displayed items

oncology breast cancer radiation oncology cancer research breast oncology cancer treatment gynecologic oncology cancer care cancer genetics genetics pathology gynecology ovarian cancer tumor biology cancer biology oncogenes molecular cancer gynecologic cancers metastasis medicinal research cancer cells molecular diagnostics cancer discovery cancer genomics surgical oncology cancer imaging cancer management hepatology thoracic oncology endocrine-related cancers hematological malignancies metastatic breast cancer genetic testing novel combination leukemia stem cell research cellular therapy cohort studies radiation therapy prognostic biomarkers molecular pathology clinical evidence radiation biology variant interpretation cell proliferation stem-cell therapy mesenchymal stem cells lynch syndrome patient response chromosomes 1 molecular plant pathology obstetrics and gynaecology cancer prevention epidemiology of cancer prognosis gastrointestinal oncology prognostic evaluation mutagenesis genetic disorders postreproductive health clinical case presentation endocrine oncology continual improvement process clinical mycology treatment and prevention international study potential predictive recurrent epithelial ovarian prognostic value primary peritoneal malignancies cell cycle progress platinum-resistant ovarian cancer ribonucleotide reductase inhibition clonal hematopoiesis li-fraumeni syndrome rad51d mutation carriers

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Prospective Study of Serum Folate Levels in Patients With Solid Tumors Treated With Olaparib. The Oncologist (2025)

pathologycancer treatmentcancer researchoncologycancer lettermalignant diseasesolid tumorsradiation oncologysurgical oncologyserum folate levelsprospective studyclinical biochemistrycancer care

A Prospective Trial of Serum Folate Levels in Women With Solid Tumor Malignancies Treated With Olaparib. Blood (2024)

cancer managementpharmacologycancer treatmentcancer researchoncologybiomarkersserum folate levelsprospective trialclinical biochemistrygynecologic oncologycancer caregynecology

CORRECTION: Soluble Urokinase Plasminogen Activator Receptor and Cardiotoxicity in Doxorubicin‑Treated Breast Cancer Patients: A Prospective Exploratory Study. Cardio-Oncology (2024)

pharmacologycancer treatmentbreast cancermedicinebreast oncologyoncologycardiovascular toxicitypharmacotherapyanti-cancer agentsprospective exploratory studycancer care

Abstract Ct055: Pavo: A Phase-II, Open Label, Single Arm Study of Niraparib in Patients With Locally Advanced/Metastatic Palb2 Mutated Tumors. Cancer Research (2023)

Tian ZhangThomas WeartMatthias WeissDrew MurrayMinaxi JhawerEdward HuynhShumei KatoAmy CummingsLydia UshaArvinder BhinderRajiv DesaiBrad JohnsonAnjali AvadhaniCecile Rose T. VibatLauren LopezBrynna DriscollAnnajane WardChristie K. RiceBlathnaid DonovanScott SherrinMykel RobbleStephanie O'LearyKimberly BlackwellAmine AziezStephanie PetroneKathleen HarndenKimberly StricklandSonya ReidMark RobsonAndrew S. PaulsonAfshin Dowlati

tumor targetingmedicineanti-cancer agentsclinical researchcancer biologymolecular cancergenitourinary cancerscancer researchmetastasistumor biologypharmacologycancer treatmentoncologyopen labelcancer caresingle arm studyoncogenesradiation oncologymedicinal research

Impact of the 2018 Acr Supplemental Screening Recommendations on Mri Eligibility in Breast Cancer Survivors. Journal of the American College of Radiology (2022)

cancer imagingbreast cancermri eligibilityoncologybreast imagingradiation oncologybreast cancer survivorsmedical imagingradiologycancer screeningcancer care

Abstract 11697: Associations of Soluble Urokinase-Type Plasminogen Activator Receptor and Doxorubicin-Related Cardiotoxicity at Standard Treatment Doses for Breast Cancer. Circulation (2021)

pharmacologyurologycancer treatmentbreast cancerbreast oncologyoncologycardiovascular toxicitystandard treatment dosespharmacotherapyabstract 11697cancer cells

A Durable Response to Pembrolizumab in a Patient With Uterine Serous Carcinoma and Lynch Syndrome Due to the Msh6 Germline Mutation. The Oncologist (2021)

Kelsey T. DanleyKaren SchmitzRitu GhaiJoy S. SclambergLela E. BuckinghamKelly BurgessTimothy M. KuzelLydia Usha

medicinetreatment and preventionlynch syndromeendocrine oncologygeneticshepatologycontinual improvement processcancer researchmolecular medicinepharmacologymedical mycologydurable responseoncologycancer geneticsuterine serous carcinomacancer carecancer immunotherapycancer imagingoncogenesclinical mycologymedicinal research

Age of Ovarian Cancer Diagnosis Among Brip1, Rad51C, and Rad51D Mutation Carriers Identified Through Multi-Gene Panel Testing. Journal of Ovarian Research (2021)

geneticspathologymulti-gene panelgenetic testingoncologyovarian cancermolecular pathologycancer geneticsovarian cancer diagnosismolecular diagnosticsgynecologic oncologygynecologyrad51d mutation carriers

Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics. The Oncologist (2021)

pathologyclinical conundrumbreast cancersurgical pathologyoncogenesbreast oncologyoncologynodal metastasiscancer genomicsradiation oncologymetastasiscancer geneticstumor biologycancer cellsmolecular diagnostics

Hypofractionated Radiation in Secretory Breast Cancer: A Case Report. Rare Tumors (2021)

Ken TatebeClaudia PerezLydia UshaRitu GhaiDian WangParul Barry

cancer biologybreast cancerradiation oncologyradiationradiation biologysecretory breast cancer

1
2
3
4
5
6
10 / page

Lydia Usha

Rush University

Affiliations

Division Of Hematology/Oncology/Cell Therapy

Rush University

NoneLydia Usha is currently serving as a Division Of Hematology/Oncology/Cell Therapy faculty at Rush University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Lydia Usha

Rush University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Prospective Study of Serum Folate Levels in Patients With Solid Tumors Treated With Olaparib. The Oncologist (2025)

pathologycancer treatmentcancer researchoncologycancer lettermalignant diseasesolid tumorsradiation oncologysurgical oncologyserum folate levelsprospective studyclinical biochemistrycancer care

A Prospective Trial of Serum Folate Levels in Women With Solid Tumor Malignancies Treated With Olaparib. Blood (2024)

cancer managementpharmacologycancer treatmentcancer researchoncologybiomarkersserum folate levelsprospective trialclinical biochemistrygynecologic oncologycancer caregynecology

CORRECTION: Soluble Urokinase Plasminogen Activator Receptor and Cardiotoxicity in Doxorubicin‑Treated Breast Cancer Patients: A Prospective Exploratory Study. Cardio-Oncology (2024)

pharmacologycancer treatmentbreast cancermedicinebreast oncologyoncologycardiovascular toxicitypharmacotherapyanti-cancer agentsprospective exploratory studycancer care

Abstract Ct055: Pavo: A Phase-II, Open Label, Single Arm Study of Niraparib in Patients With Locally Advanced/Metastatic Palb2 Mutated Tumors. Cancer Research (2023)

Impact of the 2018 Acr Supplemental Screening Recommendations on Mri Eligibility in Breast Cancer Survivors. Journal of the American College of Radiology (2022)

cancer imagingbreast cancermri eligibilityoncologybreast imagingradiation oncologybreast cancer survivorsmedical imagingradiologycancer screeningcancer care

Abstract 11697: Associations of Soluble Urokinase-Type Plasminogen Activator Receptor and Doxorubicin-Related Cardiotoxicity at Standard Treatment Doses for Breast Cancer. Circulation (2021)

pharmacologyurologycancer treatmentbreast cancerbreast oncologyoncologycardiovascular toxicitystandard treatment dosespharmacotherapyabstract 11697cancer cells

A Durable Response to Pembrolizumab in a Patient With Uterine Serous Carcinoma and Lynch Syndrome Due to the Msh6 Germline Mutation. The Oncologist (2021)

Kelsey T. DanleyKaren SchmitzRitu GhaiJoy S. SclambergLela E. BuckinghamKelly BurgessTimothy M. KuzelLydia Usha

Age of Ovarian Cancer Diagnosis Among Brip1, Rad51C, and Rad51D Mutation Carriers Identified Through Multi-Gene Panel Testing. Journal of Ovarian Research (2021)

Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics. The Oncologist (2021)

Hypofractionated Radiation in Secretory Breast Cancer: A Case Report. Rare Tumors (2021)

Ken TatebeClaudia PerezLydia UshaRitu GhaiDian WangParul Barry

cancer biologybreast cancerradiation oncologyradiationradiation biologysecretory breast cancer

1
2
3
4
5
6
10 / page